<DOC>
	<DOCNO>NCT02558296</DOCNO>
	<brief_summary>The purpose study investigate effect bexagliflozin lower hemoglobin A1c ( HbA1c ) level patient type 2 diabetes mellitus ( T2DM ) increase risk cardiovascular adverse event . The data study combine data bexagliflozin study meta-analysis CV safety outcome .</brief_summary>
	<brief_title>Bexagliflozin Efficacy Safety Trial ( BEST )</brief_title>
	<detailed_description>Approximately 130 investigative site globally plan participate study . An estimated 1650 subject inadequately control T2DM elevate risk cardiovascular adverse event randomize bexagliflozin tablet , 20 mg , placebo ratio 2:1 addition background anti-diabetic medication . The study event-driven trial . The treatment period end last randomized subject complete least 52 week treatment total least 134 subject experienced cardiac event .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Subjects diagnosis T2DM Subjects stable treatment regimen T2DM past 3 month Subjects present least one follow 3 history : Group 1 : A history atherosclerotic vascular disease Group 2 : A history heart failure Group 3 : Age ≥ 55 year diabetes ≥ 10 year , uncontrolled hypertension , currently smoke , reduce kidney function , cholesterol problem Diagnosis type 1 diabetes mellitus maturityonset/diabetes young History genitourinary tract infection Evidence abnormal liver function History MI , stroke hospitalization heart failure past 3 month Prior kidney transplant evidence kidney problem Prior plan pace maker implantation Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>